In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells by unknown
IN  VITRO  GENERATION  OF  ANTIGEN-SPECIFIC 
HEMOLYTIC  PLAQUE-FORMING  CELLS  FROM 
HUMAN  PERIPHERAL  BLOOD 
MONONUCLEAR  CELLS 
By JOHN MISITI AND THOMAS A. WALDMANN 
From the Metabolism  Branch, National  Cancer Institute,  National Institutes  of Health, 
Bethesda, Maryland  20205 
Over the past  few years there have been many advances in our understanding of 
the regulatory mechanisms that govern the humoral immune response. Many of these 
new insights have followed the development of techniques that permit the analysis of 
in vitro antibody production by antigen- or mitogen-stimulated immunocompetent 
cells.  In the mouse, detailed analysis of the mechanisms governing B cell activation 
has been made possible by the availability of assays measuring single cell antibody 
production after antigenic stimulation.  In  1963, Jerne and  Nordin  (1)  described a 
simple  technique  for elucidating  individual  antibody-forming cells  by  suspending 
lymph  node  or  spleen  cells  from  an  immunized  animal  in  a  sheep  erythrocyte 
(SRBC)l-agar matrix and observing the formation of distinct zones of complement- 
dependent erythrocyte lysis.  Further sensitivity could be obtained if lymphoid cells 
and  target erythrocytes were suspended  in monolayer without a  supporting matrix 
(2, 3).  In  1966,  Mishell and Dutton  (4, 5)  described culture conditions under which 
dissociated  spleen  cells  from  nonimmunized  mice  could  be stimulated  in  vitro  to 
generate  an  antibody  response  comparable  with  that  which  occurs  with  in  vivo 
immunization. Although the application of these techniques has vastly enhanced our 
knowledge of the regulatory mechanisms controlling antibody production by murine 
spleen cells, application of similar methodologies to the study of human  lymphoid 
elements has been limited. A few investigators (6-8) have reported successful activation 
of B cells from human tonsil. In 1973, Hoffmann et al..(6) reported the production of 
anti-SRBC  antibody by human  tonsil cells immunized with  SRBC  in  vitro under 
Mishell and Dutton culture conditions and supplemented with additional peripheral 
blood mononuclear cells (PBMC) or endotoxin from Escherichia coll.  In  1974, Watan- 
abe et al. (7) demonstrated that human tonsil cells, in the presence of 2-mercaptoeth- 
anol, could be stimulated  in vitro to respond to hapten-protein conjugates, and  in 
1976,  Fauci  and  Pratt  (8)  described a  model  for the  detection of human  tonsillar 
plaque-forming cells (PFC)  after stimulation with either SRBC or polyclonal B cell 
activators and assayed against SRBC using an ultrathin-layer gel technique. 
However, because the only readily accessible human lymphoid tissue is peripheral 
i Abbreviations used in  this paper." AET, 2-amino-ethyliso-thiouronium  bromide; FCS, fetal calf serum; 
HRBC, horse  erythrocytes;  PBMC, peripheral blood mononuclear  cells; PFC, plaque-forming  cells; PWM, 
pokeweed mitogen; SRBC, sheep erythrocytes. 
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blood, the study of human antigen-specific B lymphocyte activation is dependent on 
the development of an assay that will support the in vitro immunization of peripheral 
blood lymphoid elements. Although  established assays for measuring the polyclonal 
production  of antigen-nonspecific  antibody by human  PBMC  are  available,  there 
have been only few reported successes with antigen-specific systems. Fauci and Pratt 
(9)  described a  culture  and assay system for the stimulation  of human  PBMC  and 
subsequent measurement of direct PFC against SRBC by a hemolysis in-gel technique. 
However,  this  system  required  the  addition  of the  polyclonal  activator  pokeweed 
mitogen  (PWM).  Luzzati et al.  (10)  also reported that a  specific antibody response 
directed against SRBC could be induced in vitro. However, this system also required 
the addition of a nonspecific activating agent, Epstein-Barr virus. Hoffmann (11)  has 
generated a PBMC antigen-specific response that requires both a proliferative stimulus 
such as heat-inactivated Staphyloccocus aureus and the addition of monocyte-conditioned 
medium  containing  a  macrophage-produced  B  cell-differentiating  factor,  and  Del- 
fraissy et al. (12)  described a method for the induction of a primary in vitro antigen- 
specific antibody response by PBMC using the hapten trinitrophenyl conjugated  to 
a  carrier,  polyacrylamide  beads,  which  possess  polyclonal  stimulatory  properties. 
Alternatively,  Dosch  and  Gelfand  (13)  have  succeeded  in  generating  an  antigen- 
specific  primary  humoral  immune  response  against  both  ovalbumin  and  SRBC 
without  the addition  of other stimulatory agents.  However, their assay entails PFC 
enumeration on poly-L-lysine-coupled erythrocyte monolayers in Microtest II plates. 
Such  an  assay is  technically  difficult  and  supports  the  generation  of exceptionally 
small plaques. 
It is the purpose of this paper to describe a method for the creation of macroscopic 
hemolytic plaques by antigen-specific PFC generated from human PBMC that were 
sensitized in vitro with SRBC  in the absence of nonspecific stimulatory agents. The 
induction of PFC was dependent on the presence of adherent cells and a radiosensitive 
helper T  cell as well as appropriate B cell precursors in the culture system. 
Materials and Methods 
Materials.  Wash  media consisted  of a  balanced  salt  solution  lacking Mg  ++,  Ca  ++,  and 
plasma or other protein source.  Culture media consisted  of RPMI  1640 with 25 mM Hepes 
buffer supplemented with  penicillin  (100 U/ml), streptomycin (100 #g/ml), L-glutamine (2 
mM), 2-mercaptoethanol (5 X 10  -5 M), and 10% heat-inactivated human plasma. Heparinized 
plasma for use in the culture media was obtained from donors with untreated common variable 
hypogammaglobulinemia and  was  heat  inactivated at  56°C  for 30  min.  Plasma from four 
different  patients  was  tested,  and  all  four  were  capable  of supporting  PFC  generation. 
Hypogammaglobulinemic plasma was  used  to  avoid  false  plaques  or  the  requirement  for 
preabsorption with SRBC. However, when plasma from normal donors was tested, comparable 
results were obtained. In contrast, fetal calf serum (FCS) could not be substituted for human 
plasma at any stage in the cell culture or separation procedure because it led to suppression  of 
the PFC response.  In most cases, plasma was used unabsorbed. However, where the effect of 
absorption with SRBC was to be analyzed, plasma was first heat inactivated and then serially 
absorbed three times at 4°C with washed packed SRBC at a ratio of 1:9, packed SRBC:plasma, 
respectively. After absorption residual  erythrocytes were separated from the plasma by centri- 
fugation at 2,250 g for 10 min. SRBC and horse erythrocytes, the antigens used in the present 
study, were washed three times in phosphate-buffered saline  (pH 7.4) before addition to the 
culture. Various numbers of erythrocytes were added to the cultures in a final volume of 100 
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development of plaques  was  rehydrated, absorbed  with  SRBC  at  a  ratio of 7:1  (vol:vol), 
complement to packed erythrocytes, stored at -20°C, and used undiluted. 
Cell Preparation and Induction of PFC.  To obtain the cells for in vitro generation of antibody, 
heparinized human peripheral blood diluted with an equal volume of a balanced salt solution 
lacking Mg  ++  and  Ca  ++  was  layered  over  4.5  ml  of Ficoll-diatrizoate solution  (Bionetics 
Laboratory Products, Litton Bionetics, Inc., Kensington, Md.) in 15-ml plastic centrifuge tubes 
(model 2095;  Falcon Labware, Oxnard, Calif.), and centrifuged at room temperature for 30 
min at 550 g. PBMC were collected from the interfaces, washed three times with wash media, 
and resuspended in culture media at the appropriate cell concentration discussed below. These 
human  PBMC suspended in culture media were cultured in  1-ml vol in sterile 35-mm tissue 
culture dishes (model 25000;  Coming Glassworks, Science Products Div., Corning, N. Y.) with 
or without antigen. We found that  the size and shape of the culture vessel were critical. No 
response was  observed when  PBMC  were cultured  in  microtiter plates or round-bottomed 
tubes. 
Cultures were incubated at 37°C in a humidified atmosphere of 5% CO2 in air. Throughout 
the incubation period, cultures were rocked on a  Belleo rocker platform (model 7740;  Bellco 
Glass, Inc., Vineland, N. J.)  with an oscillation rate of 7 cycle/rain, and supplemented daily 
with  75 #1  of culture media containing  10%  human  plasma from  a  patient  with  common 
variable  hypogammaglobulinemia.  After  incubation  for  periods  indicated  in  the  Results, 
cultures were transferred to 15-ml plastic tubes (model 2057;  Falcon Labware) and centrifuged 
at 550 g for 15 min. The cell pellets were washed twice and resuspended in 200 #1 RPMI  1640 
supplemented with 25 mM Hepes buffer. At the time of plaquing, these cells were mixed with 
20  #1  of complement,  20  #1  of heat-inactivated  FCS  (Reheis,  Phoenix,  Arizona),  various 
concentrations of packed erythrocytes, and  various volumes of 1.12% agarose  (Sea  Plaque, 
Marine Colloids, Inc., Rockland, Maine), preheated to 43°C.  The optimal concentration of 
packed erythrocytes and agarose needed for the preparation of a uniform erythroeyte monolayer 
varied with erythrocytes from different species. Appropriate concentrations of erythrocytes and 
agarose had to be defined for each type of target cell employed. We found that 40 #1 of SRBC 
adjusted to a  hematocrit of 30 with 30 #1 of 1.12% agarose, and 40 #1 of horse erythrocytes 
(HRBC)  adjusted to a  hematocrit of 30 with 5 #1 of 1.12% agarose added to the cultured cell 
suspensions described above resulted  in  the  formation of homogeneous  SRBC  and  HRBC 
monolayers, respectively. 
Enumeration  of PFC.  PFC  were  enumerated  using  a  modification  of the  Cunningham 
technique (2, 3). Shallow chambers were constructed by applying a piece of z/~-in-wide double- 
coated tape  (Scotch brand 666;  Minnesota Mining & Mfg. Co., St.  Paul,  Minn.)  vertically 
down the center and at each end of a clean 75- ×  25-mm unfrosted microscope slide (model 
75001;  Kimble Products, Toledo, Ohio), dividing the slide into two rectangles of equal area. A 
second slide was pressed firmly onto  the first slide covering both chambers.  Using a  l-era  3 
syringe and a  26-gauge needle, each chamber was filled with ~ 100 #1 of the cell suspension. 
After gelation, untaped edges of the chambers were sealed with molten paraffin-petrolatum 
(Fisher Scientific Co., Pittsburgh, Pa.), premixed at a ratio of 3:1, paraffin to petrolatum, to 
prevent drying. The chambers were incubated at 37°C for 2-3 h allowing for the development 
of macroscopic plaques. The number of hemolytic plaques generated on the coded slides was 
enumerated by microscopic inspection at magnification ×  40. Only those plaques in which a 
central cell could be identified were counted. 
A reverse hemolytic plaque technique was used to measure the total number of IgM-secreting 
cells in the SRBC stimulated cultures. Such reverse plaques were assayed on a  monolayer of 
protein A-treated SRBC  (protein A/Staphylococcus aureus; Pharmacia, Uppsala, Sweden). The 
protein A was coupled to SRBC with CrCI3 as previously described (14). The assay procedure 
used was identical with that described above for antigen-specific plaques with the exception 
that 20 p.l of undiluted rabbit anti-human immunoglobulin with specificity for IgM was also 
added  to  the assay system  in  order to  quantiate  all cells producing IgM  immunoglobulin 
molecules, and  in  so doing,  to  determine whether  the  SRBC  were  acting as  a  polyclonal 
activator. 
In studies addressing the issue of whether the plaques reflected false plaques or de novo 
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added  12 h before harvesting the cells and at the time of plaquing. Cell viability assessed by 
trypan blue exclusion was not effected when cultures were treated in this fashion. 
Adherent Cell Depletion and Enrichment.  Adherent cell-depleted and -enriched populations were 
prepared  in order to define the effects  of varying concentrations of such cells on the in vitro 
generation of PFC. These populations were prepared according to the method of Kumagai et 
al. (15) with minor modifications. Briefly, 5 million PBMC isolated by Ficoll-diatrizoate density 
gradient separation were washed and resuspended in culture media with  10% human plasma. 
The mononuclear cells were then incubated in 35-mm plastic culture dishes for 1 h at 37°C in 
5% CO2 in humidified air. Nonadherent cells were collected, washed, and resuspended in media 
for culture. Adherent cells were harvested from the dishes  by vigorous scraping with a rubber 
policeman and collected in a balanced salt solution lacking Ca  ++ and Mg  ++ and supplemented 
with 0.002 M  EDTA. The cells were then washed three times and resuspended in media for 
culture.  The adherent  cell  population was >50% esterase  positive whereas  the nonadherent 
population was <5% esterase  positive. 
Preparation of Non-T Cells.  To define the T  helper cell  requirement  for the generation of 
PFC, T cell-depleted populations (B cell-and adherent cell-enriched) were prepared. To produce 
the  T  cell-depleted  population,  SRBC  treated  with  2-amino-ethyliso-thiouronium  bromide 
(AET) (16) were added to PBMC at a ratio of 150:1, AET-SRBC:PBMC, and suspended in a 
balanced salt solution supplemented with  10% human plasma. The cells were pelleted at 200 
g for 8 min and incubated at 4°C for 1-2 h. After incubation, the cells were gently resuspended 
in an equal volume of balanced salt solution, layered over a  Ficoll-diatrizoate gradient,  and 
sequentially centrifuged at 400 g for 20 min and at 2,250 g for 7 min. The population of cells 
remaining at the interphase was collected, washed, and resuspended in culture media. This cell 
population contained <3% rosetted cells and a variable percentage of monocytes. 
Preparation of T Cells.  Because the SRBC rosetting cell population contained some B cells 
with SRBC receptors, precursors for PFC in this assay, the T  cells required for these studies 
were  purified  using  the  technique  of rabbit  anti-human  (Fab')2 cellular  immunoabsorbent 
chromatography to remove surface immunoglobulin-positive cells.  The technique of immu- 
noabsorbent  chromatography, which has  been  described  previously  (17,  18), was  modified 
slightly in this study. Briefly,  PBMC isolated by Ficoll-diatrizoate density-gradient centrifuga- 
tion and suspended in RPMI 1640 media supplemented with 2.5 mM EDTA were applied to 
a column containing purified rabbit  anti-human  (Fab')2 fragments covalently conjugated to 
Sephadex  G-200 bead  polymers  (Pharmacia  Fine  Chemicals,  Inc.,  Piscataway,  N. J.).  The 
columns before cell application were equilibrated with RPMI 1640-EDTA buffer. The T cell- 
enriched population was eluted from the column with 15 ml of buffer, washed, and resuspended 
in media for culture. 
Results 
Using the basic culture and assay procedure discussed in Materials  and Methods, 
human PBMC could be stimulated by SRBC in the absence of nonspecific polyclonal 
activators  to  become  cells  that  synthesize  and  secrete  specific  antibody.  In  the 
following sections we consider  the critical  conditions  required  for the  generation  of 
antigen-specific  macroscopic PFC,  including  the  definition  of such  elements  of the 
system  as  the  optimal  dose  of antigen,  length  of culture  period,  concentration  of 
PBMC required, and plasma requirements.  In addition, the specificity of the reaction 
and requirements  for T  cells and monocytes were determined. 
Definition of Antigen Requirements.  We studied  the effect of different concentrations 
of SRBC  antigen  added  at  the  initiation  of the  culture  period  by  evaluating  the 
number of PFC generated when PBMC from three different normal individuals were 
exposed to varying concentrations of SRBC in culture.  In these experiments,  5 ×  106 
PBMC were co-cultured for 11 d with various concentrations of antigen ranging from 
0 to 10  a SRBC/culture. All cultures were rocked throughout the period of incubation, 
and  supplemented  daily with  75/~1  of culture  media containing  10%  human  hypo- JOHN  MISITI AND  THOMAS  A.  WALDMANN  1073 
gammaglobulinemic  plasma.  As  shown  in  Fig.  1,  no  PFC  were  generated  in  the 
absence of exogenous antigen. Maximal  PFC responses were observed with antigen 
concentrations ranging from 106 to  10  7 SRBC/culture. On average, the peak response 
occurred with 5 ×  106 SRBC/culture. Furthermore, antigen concentrations in excess 
of 10  7 SRBC/euhure markedly inhibited or abrogated the PFC response. Based on 
these observations, the optimal antigen concentration, 5  ×  106 SRBC/cuhure,  was 
used in all further studies. 
PFC Generation as a Function of the Length of the Culture Period.  In studies reported by 
others, the maximal PFC response was found to occur between 5 and 8 d of culture 
in  both  PWM-activated  human  cultures  assayed  for  polyclonal  immunoglobulin 
production  by the  reverse hemolytic plaque  assay  (19),  as  well  as  several  human 
antigen-specific assays previously cited  (9-12).  Because significant  variation  in  the 
optimal incubation time varies with the assay, we readdressed this issue in our system. 
5  million  PBMC  from each of three different normal  individuals were co-cultured 
with 5 ×  106 SRBC under optimal culture conditions and harvested at various times. 
No anti-SRBC response was observed until the 5th d of culture (Fig. 2). As the period 
of incubation was extended beyond day 5, PFC generation was observed. The response 
peaked between days 9 and 12 of incubation with a rapid fall in this response by day 
15.  It  should  be  noted  that  there was  individual  variation  in  the  day  of optimal 
response.  Although  no one day  represented  100%  of the  maximal  response  for all 
individuals, based on the results in Fig. 2, we have selected an incubation time of 10 
or 11 d  for all subsequent studies. 
The  Number of PBMC Required for  the  Optimal  PFC Response.  The  assays  of both 
Dosch  and  Gelfand  (13)  and  Delfraissy et  al.  (12)  suggest  that  a  significant  PFC 
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Fio.  1.  The effect of varying the antigen concentration on the number of PFC generated. 5 million 
PBMC from three separate individuals were cultured with various numbers of SRBC. The number 
of plaques generated at each antigen concentration was normalized to the percent of the maximum 
response observed for each individual.  Each point in the figure represent the mean of the percent 
maximum response for each of three individuals -1- SEM. 10( 
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FIG.  2.  The time-course of the anti-SRBC response. 5 million PBMC from three separate individ- 
uals were cultured  with 5  million  SRBC  and  the  PFC  response assessed on different  days.  The 
number of plaques generated at each time period was normalized to the percent of the maximum 
response observed for each individual. The points on the figure represent the mean of the percent 
maximum response for all three individuals ±  SEM. 
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Fro.  3.  Plaque-forming cell generation as a function of the number of PBMC cultured. Increasing 
numbers of PBMC were cultured for 11 d with 5 X 10  6 SRBC and the PFC response measured. The 
response at  each  PBMC  concentration  is  expressed  as  the  percent  of the  maximum  response 
observed. Each point represents the mean of three replicate cultures ±  SEM. JOHN MISITI AND THOMAS A.  WALDMANN  1075 
response could require up to 5 X  106-10 X  106 PBMC/culture. Other human antigen- 
specific  assays  require  far  fewer  cells  (10,  11),  and  human  culture  systems  using 
polyelonal  stimuli  such  as  PWM  require  as  few as  106  PBMC/culture  to obtain  a 
PFC  response  (19).  We  designed  a  series  of experiments  to  define  the  minimum 
number of cells required to generate a  PFC response of significant amplitude and yet 
remain on the linear portion of the curve relating PFC response to the number of cells 
cultured.  Graded numbers of PBMC ranging from 0 to  107 cells from three different 
normal  individuals  were cultured with 5  ×  106 SRBC under optimal culture condi- 
tions.  After  11  d  of incubation,  cells were harvested  and the PFC were enumerated. 
As can be seen in Fig. 3, cultures containing from 0 to 2.5 ×  106 PBMC generated few 
plaques.  A sharp increment in the number of PFC is seen with higher cell concentra- 
tions, with a  linear relationship  between cell density and PFC response in the range 
between  5  ×  106  and  5  ×  107  PBMC/culture.  Based  on  these  observations,  we 
routinely chose to culture  5  ×  106 PBMC in  1 ml of media in 35-mm tissue culture 
dishes. 
PFC Response of Normal Individuals.  The in vitro culture system was applied to the 
study of the  PBMC  from  19 unselected  normal  individuals.  5  million  mononuclear 
cells from each individual were cultured in triplicate with 5 ×  106 SRBC for 10-11 d 
under the conditions described above. PBMC from all individuals studied generated 
anti-SRBC  plaques  at  the completion of the culture  period.  The mean responses of 
the  different  individuals  (Fig.  4)  ranged  from 40 to  2,440  plaques  per  culture  (the 
geometric mean and SEM for all  19 individuals was 326 ×/+  1.3 plaques/culture). 
Plasma Requirements.  Appropriate supporting plasma is critical  for in vitro immu- 
noglobulin synthesis. We designed a series of experiments allowing us to evaluate the 
efficacy of either FCS, or human plasma as the protein  source in culture.  5  million 
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FIG. 4.  The number of PFC generated by PBMC from 19 normal individuals. 5 million PBMC 
from 19 normal individuals were cultured with 5 ×  10  n SRBC for 10-11 d as indicated in the text, 
and the number of anti-SRBC PFC generated was enumerated. Each point represents the mean 
response of triplicate cultures. The geometric mean response and SEM of all 19 individuals was 326 
X/+ 1.3 plaques/culture. 1076  HUMAN  IN VITRO  ANTIGEN-SPECIFIC PLAQUE-FORMING CELLS 
1,000 
8 
x 
100 
O 
#. 
P  / s 
i I 
i I 
i I 
ii  I 
i I 
1  I 
0  10  5  10  6 
NUMBER OF SRBC 
FIa. 5.  The effect of absorption  of plasma with  antigen.  Each  point represents the anti-SRBC 
PFC  response obtained when  5 ×  l0  s PBMC  from  one  individual were cultured with  various 
numbers of SRBC for 11 d in the presence of 10% human plasma unabsorbed  (O) or absorbed (O) 
with SRBC. 
PBMC were co-cultured with 5 ×  106 SRBC for 11  d  in the presence of either culture 
media supplemented with  10% heat-inactivated FCS or 10% human plasma collected 
in  preservative-free heparin  from  a  donor  with  untreated  common  variable hypo- 
gammaglobulinemia. Cells were incubated under optimal conditions. PBMC cultured 
in  the  presence of human  plasma generated  295  _+  15  plaques.  Comparable  results 
were obtained with plasma from  four of four patients with common variable immu- 
nodeficiency diseases and one of two normal individuals. Plasma from patients with 
hypogammaglobulinemia  was  used  in  all  subsequent  studies.  In  contrast  to  these 
observations  made  with  cells cultured  with  human  plasma,  there  was  no  response 
observed  with  cells cultured  in  the  presence  of FCS.  The  addition  of 5%  FCS  to 
cultures containing  10%  human  plasma resulted in a  90%  inhibition  (from 295  _  15 
to 30 _+ 5) of PFC generation. Furthermore,  1 ×  l06 PBMC exposed to FCS for several 
hours, washed free of the protein, and co-cultured with 4 ×  106 PBMC in the presence 
of 10%  human  plasma resulted in up to 60%  inhibition (observed response  115  _+ 50 
plaques) of the expected response. Thus,  it appears that  in this assay human  plasma 
is required for the generation of an antigen-specific response. Furthermore, FCS is not 
only incapable of supporting a  response  but  also  is  inhibitory.  In  addition,  PBMC 
exposed  to  FCS  are capable of suppressing a  PFC  response when  co-cultured  with 
PBMC  in the presence of human  plasma. 
Because human  plasma is required, care must be taken to eliminate the possibility 
of artifactual plaques resulting from passive transfer of specific antibody. Formation 
of such  pseudoplaques as described by Muchmore et al.  (20)  results from  the carry- 
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sera used in culture.  To avoid this problem, many groups use serum absorbed with 
the appropriate antigen before culture.  We addressed  the effect of preabsorption of 
the plasma with the antigen used in the present study, SRBC, on plaque formation 
by co-culturing 5 ×  10  n PBMC with various concentrations of antigen for 11 d under 
optimal  culture  conditions  in  the  presence  of  10%  human  plasma that  was  either 
unabsorbed or absorbed.  For absorbtion, plasma was incubated three times, for  1 h 
each  time,  at  4°C,  with  washed  packed  SRBC  at  a  ratio  of  1:9,  SRBC:plasma, 
respectively. As can be seen in  Fig.  5,  at  all SRBC  concentrations  used  during  the 
culture period, the PFC response generated in the presence of absorbed plasma was 
greater than  the number generated in the presence of unabsorbed  plasma. Further- 
more, in the absence of added antigen, absorbed plasma supported a  generous PFC 
response.  This  is  in  contrast  to  the  lack  of a  response  by  PBMC  cultured  with 
unabsorbed  plasma  in  the  absence  of added  antigen.  We  believe  the  most  likely 
explanation  for  these  observations  is  that  a  concentration  of antigen  sufficient  to 
generate a PFC response is eluted from the intact erythrocytes during the absorption 
procedure. This may explain the synthesis of anti-SRBC antibody by PBMC cultured 
in  sera  absorbed  against  SRBC  and  stimulated  by PWM  described  by Fauci  and 
Pratt (9).  Because absorbed plasma may contain unknown concentrations of antigen, 
we have chosen to use unabsorbed plasma in all cultures. To determine whether the 
plaques generated by cells stimulated  in the presence of unabsorbed  hypogammag- 
lobulinemic  plasma  reflected  antibody-synthesizing  cells  or,  alternatively,  false 
plaques resulting from the passive carry-over of antibody, cells were cultured  in the 
presence of cycloheximide, a  drug that  inhibits  de novo antibody synthesis but  not 
false plaque formation. The addition of this drug to cultures  12 h before cell harvest 
and  at  the time of plaquing  reduced  the  number of plaques  from 501  ±  18  in  the 
control cultures to 40 +  18 in the treated cultures, a greater than  10-fold reduction in 
plaque  formation. This response to cycloheximide demonstrates the dependence on 
de  novo  protein  synthesis  for  the  generation  of  a  plaque-forming  response,  and 
eliminates  the  possibility that  the  response measured  by this  assay  is the  result  of 
pseudoplaque formation. 
Dependence on Complement for Plaque Development.  The absolute dependence on com- 
plement in the postculture plaque-forming assay was shown in a series of experiments 
in which  PBMC  from four individuals were cultured  under optimal conditions  and 
plaqued with and without complement. The PFC response enumerated in the presence 
of complement ranged  from  135  to 630  plaques/culture,  whereas,  no response was 
elicited when cells were plaqued in its absence. 
Specificity  of the Antibody  Response.  The  specificity  of the  antibody  response  was 
assessed  by  culturing  PBMC  with  antigens  and  then  plaquing  against  both  the 
immunizing as well as unrelated  target cells.  5 million PBMC were cultured  with 5 
×  106  SRBC  or  10  v HRBC, the antigen  concentration  found to be optimal for the 
anti-HRBC  response.  Sensitized  cells  were  then  plaqued  against  both  SRBC  and 
HRBC. As can be seen in Table I, cells sensitized to SRBC generated 290 +  11  anti- 
SRBC but no anti-HRBC plaques.  Similarly, PBMC sensitized to HRBC generated 
110  ±  5  anti-HRBC  but  only 5  +-  1 anti-SRBC  plaques  per culture.  These results 
demonstrate the high degree of specificity of the antibody response for the sensitizing 
antigen.  However, we have observed that  PBMC  sensitized  to erythrocytes of more 1078  HUMAN  IN VITRO  ANTIGEN-SPECIFIC  PLAQUE-FORMING CELLS 
TABLE  I 
Hemolytic Plaques Generated by Sensitized PBMC against the Immunizing 
and an Unrelated Antigen 
Sensitizing erythrocytes 
Hemolytic plaques 
Anti-SRBC*  Anti-HRBC* 
SRBC  290 ±  11  0 
HRBC  5±  1  110+5 
* The hemolytic plaque response is expressed as the mean number of plaques 
generated by three replicate cultures ± SEM. 
TABLE II 
Lack of Polyclonal Stimulation by SRBC 
Reverse plaques (devel- 
Sensitizing cells  Anti-SRBC-specific  oped with an anti°IgM 
plaques*  antibody)  *:I: 
None  0  688 + 64 
SRBC  32 +  7  922 ±  112 
* 5 million  PBMC  were cultured for  11  d  in  the presence or absence of antigen 
(SRBC).  The  number  of antigen-specific  and  the  number  of reverse anti-IgM 
plaques  generated  by each culture were enumerated.  Each  value represents  the 
mean of three replicate cultures expressed as the number of plaques per 106 cells 
cultured ± SEM. 
:1: The polyclonal IgM response was assessed by enumerating the IgM-secreting cells 
by a reverse plaque technique developed with an anti-IgM antibody. The difference 
in the number of anti-lgM reverse plaques from cultures with and without antigen 
is not statistically  significant (P > 0.2). 
closely related species (i.e., sheep and  bovine)  generate a  PFC response with consid- 
erable cross-reactivity (data not shown). 
Nonpolyclonal  Nature  of the  Response  to the SRBC Antigen.  A  major shortcoming of 
several of the presently available human  culture systems used  for the generation of 
antigen-specific PFC is the presence ofpolyclonal activators in the cultures (9,  10,  12). 
No known polyclonal activators were used in the assay described here. However, one 
cannot  preclude the possibility that  the antigen itself (SRBC)  may have polyclonal 
stimulatory properties. We addressed this possibility with  a  series of experiments in 
which PBMC  were co-cultured with either no antigen or with 5  ×  106 SRBC.  After 
11  d  of incubation, the cells were harvested and plaqued against either SRBC alone, 
or staphlococcal protein A-bound SRBC plus an anti-IgM developing reagent. Those 
assays  that  include  staphylococcal  protein  A-treated  SRBC  and  anti-IgM  would 
enumerate all cells producing IgM, not solely those producing anti-SRBC antibody, 
and  are thus  a  measure  of polyclonal immunoglobulin  production.  The  results are 
shown  in Table II. PBMC  that  were  not  exposed to antigen  generated  no  antigen- 
specific  plaques,  whereas  when  evaluated  in  a  modified  reverse  hemolytic  plaque 
assay,  the  same  cells  generated  688  ±  64  anti-IgM  plaques/106  cells  cultured. 
Alternatively, PBMC  exposed to antigen generated 32 +  7 antigen-specific plaques/ 
10  ~ cells cultured, whereas in the reverse hemolytic plaque assay, 922  +  112 plaques 
were generated.  Because the number of reverse plaques generated with and without 
antigen are not significantly different (P >  0.2), one can conclude that SRBC do not 
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Requirements for Adherent  Cells and T  Cells for the Antibody Response.  The requirement 
for adherent ceils for the antibody response in this culture system was  determined 
using cultures of cells depleted of adherent cells and cultures of adherent cell-depleted 
populations that were reconstituted with graded numbers of adherent cells. 5 million 
PBMC depleted of plastic adherent cells were cultured under optimal conditions with 
SRBC.  Similarly, 4  x  106 nonadherent  cells were cultured alone and  with  graded 
numbers of adherent ceils. The results are shown in Fig. 6. Nonadherent cell-depleted 
populations generated 20 -  5 PFC/cuhure, <10% of that generated by unseparated 
cells. The readdition of 2,000-tad irradiated adherent cells so that they constituted an 
additional 5% of the total cell population reconstituted the normal response. However, 
further addition  of irradiated adherent cells so that  they constituted an additional 
15% of the total population resulted in suppression of the expected PFC response to 
<5% of the peak response. 
Demonstration  of T  cell  dependency required  the  modifications of the  routine 
methods for obtaining T  and non-T cell populations that are indicated in Materials 
and Methods. Non-T cells eluted with gamma globulin from an anti-(Fab')2 column 
were  found  to  be  suppressive  when  co-cultured  with  unseparated  cells  (data  not 
shown).  Furthermore,  T  cells  purified  by  AET-SRBC  rosetting  techniques  were 
consistently contaminated by cells with anti-SRBC  PFC capacity. This later obser- 
vation is most likely caused by a  population of B cells with SRBC surface receptors 
that co-purify with the rosetted T cells. To circumvent these problems, we co-cultured 
T  cells derived from mononuclear cells that did not adhere to an anti(FAB')2 column 
(>95% T  cells, as assessed by rosetting with SRBC), and non-T cells obtained from 
cells  that  did  not  form rosettes with  AET-SRBC.  The results of these studies  are 
illustrated  in  Table  III.  Neither  T  cells  nor  non-T  cells  alone  were  capable  of 
generating a PFC response. However, activity was restored by co-cuhuring 4 X  106 T 
cells with 106 non-T cells. It should be noted that in this system, 2,000-rad irradiated 
600 
5OO 
x 
tt~ 
200 
0  <t 
100 
0  r-a--i 
x  lO8  4  x  loe  ~  lo8  4  ""x'"1o6 
unseparated  nonadherent nonadherent  nonadherent 
+  + 
5% adherent  15% adherent 
Fro.  6.  Requirements for adherent cells. PBMC were cultured Unseparated, after the removal of 
plastic adherent cells and  after the readdition of an  additional 5  or  15%  plastic adherent cells. 
Plastic adherent cells were treated with 2,000 rad irradiation before their addition to the cultures. 
Each bar represents the mean response of triplicate cultures +  SEM. 1080  HUMAN  IN  VITRO  ANTIGEN-SPECIFIC  PLAQUE-FORMING  CELLS 
TAnLE III 
The Anti-SRBC Response Is T Cell Dependent 
Cells cultured*  PFC response/culture 
5 X  106 unseparated cells 
5 X  106 non-T cells 
5 X  106 T  cells 
1 X  106 non-T cells +  4 X  10  n T  cells 
1 x  106 non-T cells:~ +  4 X  106 T  cells 
1 X  106 non-T cells +  4 x  106 T  cells:J: 
40±8 
0 
0 
69 ±  29 
0 
0 
* Non-T cells were negatively selected by AET-SRBC rosetting. T  cells were 
negatively selected by anti-(Fab')2 immunoabsorbent chromatography. Cells 
treated with 2,000 rad irradiation  are indicated by double dagger (:~). The 
number of PFC recorded represents the mean of triplicate cultures ±  SEM. 
T  cells are not capable of providing sufficient help to generate an antibody response. 
This suggests that one or more of the T  cells required to provide antigen-specific T 
cell  help  is  radiosensitive to  2,000  rad.  The  alternative  possibility  that  the  T  cell 
population  was  contaminated  by B  cells  and  that  the  non-T cell  population  was 
providing  a  radioresistant  accessory cell  necessary  for  those  B  cells  to  synthesize 
antibody was excluded by the observation that synthesis could not be demonstrated 
by co-cultures of T  cells and irradiated (2,000 rad) non-T cells. 
Based on  these observations, we  concluded that  the  human  in  vitro anti-SRBC 
response generated in this culture and assay system is dependent on both T  cells and 
adherent cells, and  furthermore, at  least  one subpopulation  of T  cells required for 
antigen-specific antibody production is sensitive to 2,000 rad irradiation. 
Discussion 
The potential  importance of an  in  vitro antigen-specific PFC  culture and  assay 
system to the study of the mechanisms of human peripheral B cell activation can be 
inferred from the vast contribution such a technique has made to our understanding 
of the cellular interactions associated with murine spleen cell activation by antigen. 
Unfortunately, attempts at establishing a  reproducible culture system for a  specific 
antibody response that  requires  no polyclonal activators and  that  is  applicable  to 
humans and, in particular, human  PBMC, have generally not met with success. In 
this paper, we have described culture conditions suitable for the in vitro induction of 
an antigen-specific primary antibody response by human PBMC, and a technique by 
which this response can be reproducibly quantitated. This assay has several advan- 
tages  over previously described  human  antigen-specific systems.  The culture  tech- 
niques described by Fauci and Pratt (9), Luzatti et al. (10), Delfraissy et al. (12), and 
Hoffmann  (11), require the  addition  of polyclonal activators  (PWM,  Epstein-Barr 
virus, haptenated carriers possessing polyclonal stimulatory capacity [polyacrylamide 
beads]), or proliferative stimuli (heat-inactivated S. aureus). The culture system detailed 
in  this  paper  is  solely  dependent  on  an  antigen  (SRBC)  that  itself possesses  no 
demonstrable nonspecific stimulatory activity. Other reported assay techniques such 
as that described by Dosch and Gelfand (13), although requiring no stimulus other 
than antigen, involve a methodology for the development of plaques that is technically 
difficult to reproduce and results in the generation of microscopic plaques.  Further- 
more, the time available for the generation of plaques and their subsequent ChUrner- JOHN MISITI AND THOMAS A. WALDMANN  1081 
ation is restricted by the relatively rapid deterioration of the erythrocyte monolayers 
constructed by this technique. We have found that fixation of the target erythrocytes 
and the sensitized mononuclear cells in an agarose matrix with complement results in 
monolayers that are stable over time allowing for a  sufficient incubation period for 
the generation of large, macroscopic plaques. 
The success of this system can be attributed to several critical factors. Optimal cell 
density is essential. Large numbers of PBMC must be cultured in order to generate a 
response. Because the number of antigen-specific B and T  lymphocyte precursors are 
probably in low frequency in the nonimmunized host, it is not surprising that large 
numbers of cells per culture would be required to insure an appropriate repertoire of 
cells  for an  antigen  specific response.  Prolonging the  incubation  time to  10-12  d, 
continuous rocking during the entire period of incubation,  culturing in  large  flat- 
bottomed culture dishes  in  the  presence of human  plasma,  daily supplementation 
with culture media and plasma, and appropriate antigen concentration are all vital 
to the generation of antigen-specific PFC. Furthermore, plaquing sensitized PBMC in 
target cell monolayers fixed in an agarose matrix with the appropriate concentration 
of antigen  for  incubation  periods  of 2-3  h  is  essential  for the  formation of large 
hemolytic plaques. 
It  is  imperative  that  the  plaques  generated  in  an  assay  be  shown  to  represent 
antibody production and not the formation of false plaques.  Absorbed plasma was 
not routinely used in our assays. However, we are confident that plaque formation is 
the product of de novo protein synthesis because plaque formation was inhibited by 
the addition of cycloheximide to the culture system. 
This culture system can be used to study the cellular interactions and regulatory 
mechanisms involved in human antigen-specific antibody production in vitro because 
it can be demonstrated that  the response to SRBC  in this system is dependent on 
populations of both T  cells and  plastic-adherent cells. Of particular interest  is the 
finding that helper T cell function in this response is sensitive to 2,000 rad irradiation. 
Thomas  et  al.  (21)  have  shown  that  antibody  production  by  PWM-stimulated 
peripheral  blood  B  cells  is  augemented  by  prior  irradiation  of the  T  cells  when 
cultured at  high T:B cell ratios, whereas,  antibody production is  reduced by such 
irradiation at low T:B cell ratios. Lipsky (22)  observed a similar apparent radiosen- 
sitivity of the T  cell help required for the in vitro staphlococcal protein A  system 
when examined with low T:B cell ratios. These observations suggest the presence of 
both a  radiosensitive and  radioresistant  helper T  cell population. We have further 
suggested that the two T  helper cell populations differing in terms of their radiosen- 
sitivity can be differentiated in terms of their reactivity with an antibody that reacts 
with activated T  cells termed anti-Tat antibody (23). Distinct populations of helper 
T  cells  that  can  act  independently and  synergistically in  in  vitro antigen-specific 
antibody production have been identified in the murine system (24-28). Marrack and 
Kappler (24), and Tada et al.  (26), defined both on Ia  + antigen-nonspecific and an 
Ia- antigen-specific helper T  cell population that could be further separated on the 
basis  of  nylon  wool  adherence.  Two  independent  murine  splenic  helper  T  cell 
populations capable of functioning synergistically and characterized by differences in 
both radiosensitivity and nylon wool adherance have been described by Agarossi et 
al. (28). We have shown that the human antigen-specific anti-SRBC response elicited 
by the technique described in this paper is dependent on at least one radiosensitive 1082  HUMAN  IN VITRO ANTIGEN-SPECIFIC PLAQUE-FORMING CELLS 
helper  T  cell  population.  Whether  other  T  cell  subsets  are  required  for  the  full 
expression of this response has yet to be determined. 
Summary 
We  have  described  a  culture  and  assay  system  for  the  sensitization  of human 
peripheral blood mononuclear cells with a  T  cell-dependent antigen, sheep erythro- 
cytes,  in  the  absence  of nonspecific  stimulatory  agents  and  with  the  subsequent 
generation  of macroscopic  hemolytic plaques.  We  have  shown  that  the  antibody 
produced by the plaque-forming cells generated in this cuture system is specific for 
the sensitizing antigen,  and  that  the plaques created are not  false plaques because 
their  formation  is  inhibited  by  cycloheximide. The  success  of this  system  can  be 
attributed  to  several  critical  factors  including  large  numbers  of peripheral  blood 
mononuclear cells  (5  ×  106/culture), a  prolonged period  of incubation  (10-11  d), 
continuous rocking during the entire period of incubation, culturing in large (35-mm) 
flat-bottomed culture dishes in the presence of human plasma, and the appropriate 
antigen concentration (5 ×  106 sheep erythrocytes/culture). Furthermore, the gener- 
ation of macroscopic hemolytic plaques requires plaquing sensitized peripheral blood 
mononuclear  cells  in  target  cell  monolayers  fixed  in  an  agarose  matrix  with  an 
incubation period of 2-3 h. We have further shown that the antigen-specific response 
measured by this system is dependent on adherent cells and T  lymphocytes. At least 
one population of the helper T  cells is sensitive to 2,000 rad irradiation. This system 
is simple, sensitive, and should serve as an effective tool for the analysis of cellular 
interactions  involved  in  the  generation  of human  antigen-specific plaque-forming 
cells, the genetic control the human  immune response, and  the pathophysiology of 
altered immunoregulation in disease. 
Received  for publication 1June 1981. 
References 
1. Jerne,  N.  K.,  and  A,  A.  Nordin.  1963. Plaque  formation in  agar by single  antibody- 
producing cells. Scunce (Wash. D. C.).  140:405. 
2.  Cunningham, A. J.  1965. A method of increased sensitivity for detecting single antibody- 
forming cells. Nature (Lond.).  207:1106. 
3.  Cunningham, A. J., and A. Szenberg.  1968. Further improvements in the plaque technique 
for detecting single antibody-forming cells. Immunology. 14:599. 
4.  Mishell,  R.  I.,  and  R.  W.  Dutton.  1966. Immunization  of normal  mouse  spleen  cell 
suspensions in vitro. Science (Wash. D. C.).  153:1004. 
5.  Mishell, R. I., and R. W. Dutton.  1967. Immunization of dissociated spleen cell cultures 
from normal miee.J. Exp.  Med.  126:423. 
6.  Hoffman, M. K., D. Schmidt, and H. F. Oettgen.  1973. Production of antibody to sheep 
red blood cells by human tonsil cells in vitro. Nature (Lond.).  243:408. 
7.  Watanabe,  T.,  K.  Yoshizaki,  T.  Yagura,  and  Y.  Yamamura.  1974. In  vitro antibody 
formation by human tonsil lymphocytes. J. Immunol. 113:608. 
8.  Fauci, A. S., and K. R. Pratt. 1976. Activation of human B lymphocytes.  I. Direct plaque- 
forming cell assay for the measurement of polyclonal activation and antigenic stimulation 
of human B lymphocytes.J. Exp.  Med.  144:674. 
9.  Fauci,  A. S., and K. R. Pratt.  1976. Polyclonal  activation of bone-marrow-derived lym- JOHN  MISITI AND THOMAS A. WALDMANN  1083 
phocytes from human peripheral blood measured by a  direct plaque forming cell assay. 
Proc. Natl. Acad. Sci. U. S. A. 73:3676. 
10.  Luzzati, A. L., H.  Hengartner, and  M.  H.  Schreier.  1977. Induction of plaque-forming 
cells in cultured human lymphocytes by combined action of antigen and EB virus. Nature 
(Lond.). 269:419. 
11.  Hoffman, M. K.  1980. Antigen-specific induction and regulation of antibody synthesis in 
cultures of human  peripheral blood mononuclear cells. Proc. Natl.  Aead.  Sci.  U.  S.  A.  77: 
1139. 
12.  Delfraissy, J. F., P. Galanaud, J. Dormont, and C. Wallon. 1977. Primary in vitro antibody 
response from human peripheral blood lymphocytes.  J. Immunol.  118:630. 
13.  Dosch,  H.  M., and  E.  W. Gelfand.  1977. Generation of human  plaque-forming cells in 
culture: tissue distribution, antigenic and cellular requirements. J. Immunol.  118:302. 
14.  Gronowicz, E., A. Coutinho, and F. Melchers.  1976. A plaque assay for all cells secreting 
Ig of a given type or class. Eur. J. Immunol. 6:58. 
15.  Kumagai, T., K. hoh, S. Hinuma, and M. Tada. 1979. Pretreatment of plastic petri dishes 
with fetal calf serum. A simple method for macrophage isolation.  J.  lmmunol.  Methods.  29: 
17. 
16.  Pellegrino, M. A., S. Ferrone, M. P. Dietrich, and R. A. Reisfeld. 1975. Enhancement of 
sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2- 
amino-ethyliso-thiouronium. Clin. Immunol. Immunopathol. 3:324. 
17.  Chess,  L.,  R.  P.  MacDermott,  and  S.  F.  Schlossman.  1974. Immunologic functions  of 
isolated human lymphocyte subpopulations. I. Quantitative isolation of human T  and B 
cells and response to mitogens.J. Immunol.  113:1113. 
18.  Broder, S., R. L. Edelson, M. A. Lutzner, D. L. Nelson, R. P. MacDermott, M. E. Durra, 
D.  K.  Goldman, B.  D.  Meade,  and  T.  A. Waldmann.  1976. The  Sezary syndrome.  A 
malignant proliferation of helper T  cells..]. Clin. Invest. 58:1297. 
19.  Ginsburg, W.  W.,  F.  D.  Finkelman, and  P.  E.  Lipsky.  1978. Circulating and  mitogen 
induced  immunoglobulin  secreting cells  in  human  peripheral  blood:  evaluation  by  a 
modified reverse hemolytic plaque assay.J. Immunol.  120:33. 
20.  Muchmore,  A.  V.,  I.  Koski,  N.  Dooley,  and  R.  M.  Blaese.  1976. Artifactual  plaque 
formation in vitro and in vivo due to passive transfer of specific antibody. J.  Immunol.  116: 
1016. 
21.  Thomas, Y., J. Sosman, O. Irigoyen, S. M.  Friedman, P. C. Kung, G. Goidstein, and L. 
Chess. 1980. Functional analysis of human T cell subsets defined by monoclonal antibodies. 
I.  Collaborative T-T  interactions in  the  immunoregulation of B  cell differentiation. J. 
Immunol.  125:2402. 
22.  Lipsky, P.  E.  1980. Staphylococcal protein A, a  T  cell-qzgulated polyclonal activator of 
human B cells.J. Immunol.  125:155. 
23.  Uchiyama, T., D. L. Nelson, T. A. Fleisher, and T. A. Waldmann.  1981. A  monoclonal 
antibody (anti-Tac) reactive with activated and  functionally mature human T  cells. II. 
Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one 
of two types of helper T  cells.  J. lmmunol.  126:1398. 
24.  Marrack, P. C., and J. W. Kappler. 1975. Antigen-specific and non-specific mediators of T 
cell/B cell cooperation. I. Evidence for their production by different T  cells. J.  Immunol. 
114:1116. 
25.  Keller,  D.  M., J.  E.  Swierkosz,  P.  Marrack,  and J.  W.  Kappler.  1980. Two  types of 
functionally distinct, synergizing helper T  cells..]. Immunol.  124:1350. 
26.  Tada, T., T. Takemori, K. Okumura,  M.  Nonaka, and T. Tokuhisa.  1978. Two distinct 1084  HUMAN  IN VITRO  ANTIGEN-SPECIFIC PLAQUE-FORMING CELLS 
types of helper T  cells involved in  the  secondary antibody response:  independent  and 
synergistic effects of Ia- and Ia  + helper T  cells.J. Exp.  Med. 147:446. 
27.  Janeway, C. A. Jr., R. A. Murgita, F. I. Weinbaum, W. R. Asofsky, and H. Wigzell. 1977. 
Evidence for an immunoglobulin-dependent antigen-specific helper T cell. Proc. Natl. Acad. 
Sci. U. S. A. 74:4582. 
28.  Agarossi, G., C, Mancini, and G. Doria.  1981. Synergism between two helper cell suhpop- 
ulations characterized by different radiosensitivity and nylon adherence. J.  ImmunoL 126: 
955. 